T. Feys MBA, MSc

Highlights in acute myeloid leukaemia

SUMMARY

During the 64^th annual meeting of ASH, again hundreds of interesting oral abstracts and poster presentations in the field of acute myeloid leukaemia were discussed. In this article, we will highlight some of the most promising data in the field of novel therapeutic agents, with interesting studies on gilteritinib and quizartinib. Furthermore, several trials assessed new induction strategies and reported on biomarker and/or minimal residual disease investigations. Finally, we discuss some practice-changing data from the ASAP and VIALE-A trials.

(BELG J HEMATOL 2023;14(1):30–5)

New haematology reimbursements in Belgium

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J HEMATOL 2023;14(1):36)

New haematology reimbursements in Belgium

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J HEMATOL 2022;13(7):284)

Journal Scan

SUMMARY

In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2022;13(7):285–8)

Journal scan

SUMMARY

In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2022;13(6):256–9)

Highlights in multiple myeloma

SUMMARY

During the past European Hematology Association’s annual congress (EHA 2022), four oral sessions were devoted to clinical trials and recent advances in myeloma. These sessions covered newly diagnosed multiple myeloma (MM), antibody-based therapy in relapsed/refractory (RR) MM, BCMA-directed treatment in RRMM and biology and translational research. Below, we summarise the highlights from some of the studies that were presented in each of these sessions.

(BELG J HEMATOL 2022;13(5):219–23)

Presidential symposium EBMT 2022

SUMMARY

During the presidential symposium of the 48^th Annual Meeting of the EBMT (2022), the Van Bekkum Award and seven top clinical abstracts were discussed. These presentations will be covered in this report.

(BELG J HEMATOL 2022;13(4):169–73)